← Eichor
Condition: Egfr Tki Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Egfr Tki

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
Phase 1/Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07535437Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Phase 1/Phase 2 · 1 location(s) · China Medical University Hospital · NCT06071013Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia
Phase 3 · 1 location(s) · Queen Mary Hospital, Hong Kong · NCT06643416A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Ce
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07548060Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
Phase N/A · 1 location(s) · AstraZeneca · NCT07593248Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC
Phase 3 · 1 location(s) · Instituto Nacional de Cancerologia de Mexico · NCT05852990Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma
Phase 2 · 3 location(s) · Taipei Medical University Hospital · NCT07624487Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizum
Phase 2 · 1 location(s) · Se-Hoon Lee · NCT06830694Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06924398High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-g
Phase 2 · 1 location(s) · Jialei Wang · NCT06652048CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
Phase N/A · 1 location(s) · AstraZeneca · NCT07413757Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Li
Phase 3 · 78 location(s) · ArriVent BioPharma, Inc. · NCT07185997Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations
Phase 2 · 1 location(s) · National University Hospital, Singapore · NCT06062823Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06363734Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05011487Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR
Phase 2 · 1 location(s) · Peng Zhang · NCT06755684Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT05284539Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Phase N/A · 1 location(s) · Hunan Province Tumor Hospital · NCT04324164Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Ce
NA · 1 location(s) · Chongqing University Cancer Hospital · NCT06481566Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metast
NA · 1 location(s) · Second Affiliated Hospital of Nanchang University · NCT07398599A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT01994057First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer H
Phase 1/Phase 2 · 24 location(s) · Pierre Fabre Medicament · NCT06043817IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
Phase 1/Phase 2 · 1 location(s) · InxMed (Shanghai) Co., Ltd. · NCT05994131AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients
Phase N/A · 1 location(s) · Fudan University · NCT06604689A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Phase 2 · 16 location(s) · Lantern Pharma Inc. · NCT05456256Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
Phase N/A · 1 location(s) · University of Colorado, Denver · NCT03042221Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Genera
Phase 2 · 2 location(s) · Betta Pharmaceuticals Co., Ltd. · NCT07181499A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherap
Phase 2/Phase 3 · 110 location(s) · AbbVie · NCT07155187Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）
Phase 3 · 1 location(s) · CSPC Megalith Biopharmaceutical Co.,Ltd. · NCT06927986EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Phase 1/Phase 2 · 14 location(s) · Shanghai EpimAb Biotherapeutics Co., Ltd. · NCT05176665
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.